Safety Study of a Vaccine (DENV-1 PIV) to Prevent Dengue Disease

Inclusion Criteria: * Males and females 18 years of age or the legal age of consent (whichever is greater) to 50 (inclusive) years of age * Negative screening laboratory test against dengue, Japanese Encephalitis, West Nile, and Yellow Fever viruses * Healthy * All subjects must agree to use contraception or to abstain from sex from enrollment through trial completion * Able to provide informed consent and able to be followed throughout the trial period Exclusion Criteria: * History of Flavivirus infection or history of Flavivirus vaccine (experimental or licensed product) including Japanese encephalitis, West Nile virus, Yellow fever, and dengue * Have a known or suspected hypersensitivity or adverse reaction to vaccines * Have received a live-attenuated vaccine within 42 days prior to the initial injection on Day 0 or a subunit or killed vaccine within 30 days of the initial injection on Day 0 * Are pregnant or breastfeeding * Known HIV, Hepatitis B and/or Hepatitis C infection * Have any acute illness, including an oral body temperature greater than 100.4°F at the day of vaccination * Have any occupational, social, or medical concerns that would impact subject safety, interfere with protocol adherence, or affect a subject's ability to give informed consent * Have been using immunomodulatory therapy (use of systemic corticosteroids or chemotherapeutics that may influence antibody development) within the past 6 months; medications or nutritional supplements known to or which potentially could affect organ function within 30 days prior to the initial injection * Have received an investigational drug or vaccine or participated in a drug product or vaccine study within a period of 30 days prior to Day 0 * Have received or donated blood or plasma within 90 days of Day 0 (or plan on receiving or donating blood or plasma during the study)